Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The HIV Research Group, led by Professor Philip Goulder of the Department of Paediatrics, have been awarded a multi-million pound, five year Wellcome Trust Senior Investigator award to further their work into HIV disease limitation.

The group, based in the Peter Medawar Building in Oxford, are working with clinic staff in Kimberly and Durban, (above), to investigate mechanisms of HIV disease limitation within the South African population.

These prestigious awards provide long-term stable funding for scientists with an excellent track record in their research field, and offer the flexibility and time to enable them to tackle the most important questions in their field. 

Full details of the funding are available on the Wellcome Trust website.

Similar stories

Promising discovery for treatment of neuromuscular diseases

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.